Last10K.com

Zymeworks Inc. (ZYME) SEC Filing 10-K Annual report for the fiscal year ending Monday, December 31, 2018

SEC Filings

Zymeworks Inc.

CIK: 1403752 Ticker: ZYME
Document and Entity Information - USD ($)
$ in Millions
12 Months Ended
Dec. 31, 2018
Mar. 05, 2019
Jun. 30, 2018
Document And Entity Information [Abstract]   
Document Type10-K  
Amendment Flagfalse  
Document Period End DateDec. 31, 2018  
Document Fiscal Year Focus2018  
Document Fiscal Period FocusFY  
Trading SymbolZYME  
Entity Registrant NameZymeworks Inc.  
Entity Central Index Key0001403752  
Current Fiscal Year End Date--12-31  
Entity Well-known Seasoned IssuerNo  
Entity Current Reporting StatusYes  
Entity Voluntary FilersNo  
Entity Filer CategoryAccelerated Filer  
Entity Shell Companyfalse  
Entity Small Businesstrue  
Entity Emerging Growth Companytrue  
Entity Ex Transition Periodtrue  
Entity Common Stock, Shares Outstanding 32,025,299 
Entity Public Float  $ 406.9

View differences made from one year to another to evaluate Zymeworks Inc.'s financial trajectory

Compare SEC Filings Year-over-Year (YoY) and Quarter-over-Quarter (QoQ)
Sample 10-K Year-over-Year (YoY) Comparison

Compare this 10-K Annual Report to its predecessor by reading our highlights to see what text and tables were  removed  ,   added    and   changed   by Zymeworks Inc..

Continue

Assess how Zymeworks Inc.'s management team is paid from their Annual Proxy

Definitive Proxy Statement (Form DEF 14A)
Screenshot example of actual Proxy Statement

Zymeworks Inc.'s Definitive Proxy Statement (Form DEF 14A) filed after their 2019 10-K Annual Report includes:

  • Voting Procedures
  • Board Members
  • Executive Team
  • Salaries, Bonuses, Perks
  • Peers / Competitors

Continue

SEC Filing Tools

Financial Statements, Disclosures and Schedules

Inside this 10-K Annual Report

Document And Entity Information
Consolidated Balance Sheets
Consolidated Balance Sheets (Parenthetical)
Consolidated Statements Of Cash Flows
Consolidated Statements Of Changes In Redeemable Convertible Preferred Shares And Shareholders' Equity
Consolidated Statements Of Changes In Redeemable Convertible Preferred Shares And Shareholders' Equity (Parenthetical)
Consolidated Statements Of Loss And Comprehensive Loss
Acquisition Of Kairos
Acquisition Of Kairos (Tables)
Acquisition Of Kairos - Additional Information (Detail)
Acquisition Of Kairos - Summary Of Carrying Value Of Ipr&Amp;D, Net Of Impairment (Detail)
Commitments And Contingencies
Commitments And Contingencies (Tables)
Commitments And Contingencies - Additional Information (Detail)
Commitments And Contingencies - Future Minimum Lease Payments Under Non-Cancellable Operating Leases And Capital Leases (Detail)
Financial Instruments
Financial Instruments - Additional Information (Detail)
Government Grants And Credits
Government Grants And Credits (Tables)
Government Grants And Credits - Additional Information (Detail)
Government Grants And Credits - Component Of Government Grants And Credits (Detail)
Income Taxes
Income Taxes (Tables)
Income Taxes - Additional Information (Detail)
Income Taxes - Schedule Of Income Tax Expense (Recovery) (Detail)
Income Taxes - Schedule Of Income Tax Expense (Recovery) (Parenthetical) (Detail)
Income Taxes - Schedule Of Reconciliation Of Beginning And Ending Amounts Of Unrecognized Tax Benefits (Detail)
Income Taxes - Summary Of Expiry Details Of Investment Tax Credits, Non-Capital Losses And Net Operating Losses For Income Tax Purposes (Detail)
Income Taxes - Summary Of Significant Components Of Deferred Income Tax Assets And Liabilities (Detail)
Intangible Assets
Intangible Assets (Tables)
Intangible Assets - Additional Information (Detail)
Intangible Assets - Schedule Of Intangible Assets (Detail)
Liabilities
Liabilities (Tables)
Liabilities - Schedule Of Accounts Payable And Accrued Liabilities (Detail)
Liabilities - Schedule Of Other Current Liabilities (Detail)
Liabilities - Schedule Of Other Long-Term Liabilities (Detail)
Nature Of Operations
Nature Of Operations - Additional Information (Detail)
Property And Equipment
Property And Equipment (Tables)
Property And Equipment - Additional Information (Detail)
Property And Equipment - Components Of Property And Equipment (Detail)
Recent Accounting Pronouncements
Redeemable Convertible Class A Preferred Shares And Shareholders' Equity
Redeemable Convertible Class A Preferred Shares And Shareholders' Equity (Tables)
Redeemable Convertible Class A Preferred Shares, And Shareholders' Equity - Additional Information (Detail)
Redeemable Convertible Class A Preferred Shares, And Shareholders' Equity - Schedule Of Estimated Fair Value Of Stock Options Assumptions (Detail)
Redeemable Convertible Class A Preferred Shares, And Shareholders' Equity - Schedule Of Non-Vested Stock Option Activity (Detail)
Redeemable Convertible Class A Preferred Shares, And Shareholders' Equity - Schedule Of Stock-Based Compensation Expense For Equity Classified Instruments (Detail)
Redeemable Convertible Class A Preferred Shares, And Shareholders' Equity - Summary Of Range Of Stock Options Granted (Detail)
Redeemable Convertible Class A Preferred Shares, And Shareholders' Equity - Summary Of Stock Options Granted (Detail)
Research Collaboration And Licensing Agreements
Research Collaboration And Licensing Agreements (Tables)
Research, Collaboration And Licensing Agreements - Additional Information - Beigene (Detail)
Research, Collaboration And Licensing Agreements - Additional Information - Celgene (Detail)
Research, Collaboration And Licensing Agreements - Additional Information - Daiichi Sankyo (Detail)
Research, Collaboration And Licensing Agreements - Additional Information - Daiichi Sankyo Two (Detail)
Research, Collaboration And Licensing Agreements - Additional Information - Gsk (Detail)
Research, Collaboration And Licensing Agreements - Additional Information - Gsk Two (Detail)
Research, Collaboration And Licensing Agreements - Additional Information - Janssen (Detail)
Research, Collaboration And Licensing Agreements - Additional Information - Leo (Detail)
Research, Collaboration And Licensing Agreements - Additional Information - Lilly (Detail)
Research, Collaboration And Licensing Agreements - Additional Information - Lilly Two (Detail)
Research, Collaboration And Licensing Agreements - Additional Information - Merck (Detail)
Research, Collaboration And Licensing Agreements - Schedule Of Collaborative Arrangements And Noncollaborative Arrangement Transactions (Detail)
Short-Term Investments
Short-Term Investments - Additional Information (Detail)
Subsequent Events
Subsequent Events - Additional Information (Detail)
Summary Of Significant Accounting Policies
Summary Of Significant Accounting Policies (Policies)
Summary Of Significant Accounting Policies (Tables)
Summary Of Significant Accounting Policies - Additional Information (Detail)
Summary Of Significant Accounting Policies - Schedule Of Changes In Fair Value Of Liability Classified Stock Options (Detail)
Summary Of Significant Accounting Policies - Schedule Of Changes In Fair Value Of Warrant Liabilities (Detail)
Summary Of Significant Accounting Policies - Schedule Of Financial Liabilities Measured At Fair Value On A Recurring Basis (Detail)
Summary Of Significant Accounting Policies - Summary Of Calculation Of Diluted Loss Per Share (Detail)
Summary Of Significant Accounting Policies - Summary Of Changes In Fair Value Of The Company's Liability For Contingent Consideration (Detail)
Summary Of Significant Accounting Policies - Summary Of Estimated Useful Lives (Detail)
Warrant Liabilities And Long-Term Debt
Warrant Liabilities And Long-Term Debt (Tables)
Warrant Liabilities And Long-Term Debt - Perceptive Debt - Additional Information (Detail)
Warrant Liabilities And Long-Term Debt - Summary Of Assumptions Used In Estimating Fair Value Of Warrants Determined Using Black-Scholes Option Pricing Model (Detail)
Warrant Liabilities And Long-Term Debt - Summary Of Debt (Detail)
Warrant Liabilities And Long-Term Debt - Warrant Liabilities - Additional Information (Detail)
Ticker: ZYME
CIK: 1403752
Form Type: 10-K Annual Report
Accession Number: 0001193125-19-065609
Submitted to the SEC: Wed Mar 06 2019 4:20:38 PM EST
Accepted by the SEC: Wed Mar 06 2019
Period: Monday, December 31, 2018
Industry: Pharmaceutical Preparations

External Resources:
Stock Quote
Social Media

Bookmark the Permalink:
https://last10k.com/sec-filings/zyme/0001193125-19-065609.htm